Our work on lung adenocarcinoma subtypes with biomarkers and clinically relevant vulnerabilities including immune checkpoint blockade response is now available online. This was collaborative work with great colleagues from Broad, Samsung Medical Center, Lunit, and NCI Tumor Molecular Pathology Working Group.
Whijae Roh*, Yifat Geffen*, Hongui Cha*, Mendy Miller , Shankara Anand, Jaegil Kim, David Heiman, Justin F. Gainor, Peter W. Laird, Andrew D. Cherniack, Chan-Young Ock, Se-Hoon Lee, Gad Getz, "High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities." Cancer Research (2022).